We can’t show the full text here under this license. Use the link below to read it at the source.
Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Venous Thromboembolism: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Blood Clots in Veins: A Review and Analysis of Clinical Trials
AI simplified
Abstract
A total of 39 randomized controlled trials involving 70,499 participants were included in the analysis of glucagon-like peptide 1 receptor agonists and venous thromboembolism risk.
- A nonsignificant upward trend in the risk of venous thromboembolism was observed among participants using GLP-1 receptor agonists (odds ratio 1.19).
- GLP-1 receptor agonists were significantly associated with an increased risk of deep vein thrombosis (odds ratio 1.64).
- The risk difference indicated 25 more events per 10,000 person-years for deep vein thrombosis among users of GLP-1 receptor agonists.
- Increased risk of deep vein thrombosis was particularly noted in trials with treatment duration greater than 1.5 years (odds ratio 2.32).
- A significant association with deep vein thrombosis was also found in cardiovascular outcome trials (odds ratio 2.18).
- No significant association was observed between GLP-1 receptor agonists and the risk of pulmonary embolism.
AI simplified